{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:19:41Z","timestamp":1785467981843,"version":"3.56.0"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T00:00:00Z","timestamp":1638576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014091","name":"AstraZeneca Pharma Poland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>We aimed to describe characteristics of new users of ticagrelor or clopidogrel following a recent coronary event, and to compare incidences of selected safety outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This observational cohort study used data from national Swedish registers. Patients first dispensed ticagrelor or clopidogrel (June 2011\u2013December 2013) were identified from the Prescribed Drug Register and followed until censoring or 31 December 2014. Cohorts were restricted to patients with a recent coronary event\u2010related hospital contact identified in the Patient Register.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 45\u2009987 unique, na\u00efve users of ticagrelor (73% men; mean age 66\u2009years) or clopidogrel (69% men; mean age 69\u2009years). Corresponding to indication, diagnoses before initiation were acute coronary syndrome (93%), myocardial infarction (76%), and percutaneous coronary intervention (69%). The most common medications used in the year before initiation of study therapy were antithrombotic agents (clopidogrel 62%, ticagrelor 43%), mainly low\u2010dose acetylsalicylic acid. Ticagrelor users had a higher incidence (per 1000 person\u2010years) of respiratory bleeding (24.6 [95% confidence interval (CI): 22.1\u201327.3]; vs clopidogrel users: 14.4 [13.1\u201315.8]) and dyspnea (25.9 [23.3\u201328.7]; vs clopidogrel users: 16.8 [15.4\u201318.4]). Epistaxis accounted for 83\u201393% of respiratory bleeds. Adjusted analyses found increased risks of gout and acute renal failure with ticagrelor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Clopidogrel users were older with a higher prevalence of concomitant medications than ticagrelor users. Our study showed increased incidences of dyspnea and respiratory bleeding (mainly epistaxis) among current ticagrelor users compared with clopidogrel users, and increased risks of gout and acute renal failure after adjustment.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5387","type":"journal-article","created":{"date-parts":[[2021,11,21]],"date-time":"2021-11-21T14:03:57Z","timestamp":1637503437000},"page":"235-246","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient characteristics and safety outcomes in new users of ticagrelor and clopidogrel\u2014An observational cohort study in Sweden"],"prefix":"10.1002","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2619-2189","authenticated-orcid":false,"given":"Marie","family":"Linder","sequence":"first","affiliation":[{"name":"Centre for Pharmacoepidemiology Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Andersen","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology Karolinska Institutet  Stockholm Sweden"},{"name":"Pharmacovigilance Research Center, Department of Drug Design and Pharmacology Faculty of Health and Medical Sciences, University of Copenhagen  Copenhagen Denmark"},{"name":"Research Unit of General Practice University of Southern Denmark  Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,12,4]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.017"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx393"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv320"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu278"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2002.01027.x"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.03.100"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi754"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.058"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvv034"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw284"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780100409"},{"key":"e_1_2_11_14_1","volume-title":"The European Union electronic Register of Post\u2010Authorisation Studies (EU PAS Register)","author":"European Medicines Agency (EMA)","year":"2020"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.5.608"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1294"},{"key":"e_1_2_11_17_1","volume-title":"ATC\/DDD index","author":"WHO Collaborating Centre for Drug Statistics Methodology and Norwegian Institute of Public Health","year":"2020"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/30.suppl_1.S30"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/140349489302100102"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(00)00366-1"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr236"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs215"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000404"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx419"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"e_1_2_11_29_1","volume-title":"Accessed at the Online List of Pharmaceuticals in Sweden","author":"Swedish Summary of Product Characteristics","year":"2020"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr231"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.07.015"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22063"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.05.023"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500857"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908077"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5387","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.5387","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T10:02:50Z","timestamp":1693216970000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,4]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1002\/pds.5387"],"URL":"https:\/\/doi.org\/10.1002\/pds.5387","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,4]]},"assertion":[{"value":"2020-11-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}